Clinical Activity of NX-5948 in CLL & NHL: A First-in-Class BTK Degrader
Time: 9:00 am
day: Day Two AM
Details:
- Emerging clinical data support utility of novel MOA against validated target
- Activity demonstrated in the CNS and in patients harboring BTKi resistance mutations
